UA87335C2 - Gel composition of 4-hydroxytamoxifen - Google Patents

Gel composition of 4-hydroxytamoxifen

Info

Publication number
UA87335C2
UA87335C2 UAA200705192A UAA200705192A UA87335C2 UA 87335 C2 UA87335 C2 UA 87335C2 UA A200705192 A UAA200705192 A UA A200705192A UA A200705192 A UAA200705192 A UA A200705192A UA 87335 C2 UA87335 C2 UA 87335C2
Authority
UA
Ukraine
Prior art keywords
hydroxytamoxifen
gel composition
relates
pharmaceutical compositions
gels containing
Prior art date
Application number
UAA200705192A
Other languages
English (en)
Ukrainian (uk)
Inventor
Валери Мазини-Этев
Original Assignee
Лаборатуар Безен Энтернасеналь
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Безен Энтернасеналь filed Critical Лаборатуар Безен Энтернасеналь
Publication of UA87335C2 publication Critical patent/UA87335C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение относится к фармацевтическим композициям и гелям, содержащим 4-гидрокситамоксифен.
UAA200705192A 2004-10-14 2005-10-13 Gel composition of 4-hydroxytamoxifen UA87335C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292447A EP1647271A1 (en) 2004-10-14 2004-10-14 4-Hydroxy tamoxifen gel formulations

Publications (1)

Publication Number Publication Date
UA87335C2 true UA87335C2 (en) 2009-07-10

Family

ID=34931454

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200705192A UA87335C2 (en) 2004-10-14 2005-10-13 Gel composition of 4-hydroxytamoxifen

Country Status (8)

Country Link
US (2) US20060105041A1 (ru)
EP (1) EP1647271A1 (ru)
KR (1) KR20130049841A (ru)
CN (1) CN101065120B (ru)
NZ (1) NZ554206A (ru)
RS (1) RS50759B (ru)
UA (1) UA87335C2 (ru)
ZA (1) ZA200703016B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
DE60327363D1 (de) * 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ES2456958T3 (es) * 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
DK1631275T3 (da) * 2003-06-09 2008-08-18 Ascend Therapeutics Inc Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
WO2017015125A1 (en) * 2015-07-23 2017-01-26 Anderson S Keith Stratifying breast cancer risk in women with sclerosing adenosis
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
CN108210484B (zh) * 2016-12-11 2021-06-25 复旦大学 他莫昔芬凝胶贴膏及其制备方法
WO2023026139A1 (en) * 2021-08-23 2023-03-02 Singh Divya Dhananjay Pharmaceutical composition comprising 4- hydroxytamoxifen for the treatment of mastalgia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
AU2002340120A1 (en) * 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US6695171B2 (en) * 2002-02-12 2004-02-24 Seaquistperfect Dispensing Foreign, Inc. Pump dispenser
DE60327363D1 (de) * 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
ES2456958T3 (es) * 2003-04-01 2014-04-24 Besins Healthcare Luxembourg Sarl Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
DK1631275T3 (da) * 2003-06-09 2008-08-18 Ascend Therapeutics Inc Behandling og forebyggelse af excessiv ardannelse med 4-hydroxy-tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579857A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Chemically stable compositions of 4-hydroxy tamoxifen

Also Published As

Publication number Publication date
US20060105041A1 (en) 2006-05-18
US20170224639A1 (en) 2017-08-10
CN101065120B (zh) 2010-05-05
RS50759B (sr) 2010-08-31
CN101065120A (zh) 2007-10-31
ZA200703016B (en) 2008-08-27
EP1647271A1 (en) 2006-04-19
KR20130049841A (ko) 2013-05-14
NZ554206A (en) 2010-09-30

Similar Documents

Publication Publication Date Title
UA87335C2 (en) Gel composition of 4-hydroxytamoxifen
TW200637490A (en) Fertilizer-compatible composition
SG153800A1 (en) Pharmaceutical compositions
TW200505875A (en) Novel compounds
UA94417C2 (ru) Замещенные 7-азаиндазолы, композиция, которая их содержит, и применение
IL171914A0 (en) Variants of il-18bp, their preparation and pharmaceutical compositions containing them
SE0301700D0 (sv) Novel compounds
TW200602052A (en) Azaindoles useful as inhibitors of JAK and other protein kinases
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
UA87158C2 (ru) Тестостероновый гель, содержащий пропиленгликоль в качестве усилителя проникающей способности
MY162181A (en) Compositions and methods for modulating hemostasis
TW200745122A (en) New compounds I
EA200970132A1 (ru) Аналоги морфолинила и пирролидинила
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
SG158091A1 (en) Imidazoazepinone compounds
NO20073762L (no) Visko-supplementsammensetning og fremgangsmater
MY162185A (en) Alumina particles and methods of making the same
ATE535251T1 (de) Stabile wässrige g-csf-haltige zusammensetzungen
ZA200700178B (en) Pharmaceutical composition containing polypeptide fragments of serralysins
NO20072463L (no) 4-hydroksytamoksifen gelformuleringer
AU2003259750A1 (en) Methods and compositions for targeting secretory lysosomes
EA200700580A1 (ru) Тестостероновые гели, включающие пропиленгликоль в качестве усилителя проницаемости
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent
RU2006131930A (ru) Огнезащитный состав
UA93397C2 (ru) Комбинированное противомаститное ветеринарное средство